Smad2 Antibody (YZ-13): sc-101153

Smad2 Antibody (YZ-13) is a mouse monoclonal IgG2a kappa light chain antibody that detects Smad2 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-Smad2 antibody (YZ-13) is available in a non-conjugated form, allowing for versatile experimental use. Smad2 plays a crucial role in the transforming growth factor-beta (TGF-β) signaling pathway, which is essential for regulating cellular processes such as proliferation, differentiation, and apoptosis. Smad2 is primarily located in the cytoplasm and nucleus, where Smad2 translocates upon phosphorylation in response to TGF-β signaling. This localization enables Smad2 to act as a transcription factor, regulating the expression of target genes that mediate the cellular response to TGF-β. Smad2′s ability to shuttle between the cytoplasm and nucleus underscores Smad2′s importance in cellular signaling and gene regulation, making Smad2 a key player in developmental processes and tissue homeostasis. Smad2 interacts with other Smad proteins, such as Smad3 and Smad4, to form complexes that facilitate the transcription of TGF-β target genes, further emphasizing Smad2′s role in the intricate network of cellular signaling pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Smad2 Antibody (YZ-13) References:

1. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.  |  Gaspar, NJ., et al. 2007. Mol Pharmacol. 72: 152-61. PMID: 17400764
2. TGF-beta signalling through the Smad pathway.  |  Massaous, J. and Hata, A. 1997. Trends Cell Biol. 7: 187-92. PMID: 17708943
3. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis.  |  Khalil, H., et al. 2017. J Clin Invest. 127: 3770-3783. PMID: 28891814
4. SMAD2 promotes myogenin expression and terminal myogenic differentiation.  |  Lamarche, É., et al. 2021. Development. 148: PMID: 33462116
5. SUMOylation of Smad2 mediates TGF-β-regulated endothelial-mesenchymal transition.  |  Su, Q., et al. 2023. J Biol Chem. 299: 105244. PMID: 37690680
6. A human Mad protein acting as a BMP-regulated transcriptional activator.  |  Liu, F., et al. 1996. Nature. 381: 620-3. PMID: 8637600
7. MADR1, a MAD-related protein that functions in BMP2 signaling pathways.  |  Hoodless, PA., et al. 1996. Cell. 85: 489-500. PMID: 8653785
8. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.  |  Eppert, K., et al. 1996. Cell. 86: 543-52. PMID: 8752209
9. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response.  |  Zhang, Y., et al. 1996. Nature. 383: 168-72. PMID: 8774881
10. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways.  |  Lagna, G., et al. 1996. Nature. 383: 832-6. PMID: 8893010
11. Smad6 inhibits signalling by the TGF-beta superfamily.  |  Imamura, T., et al. 1997. Nature. 389: 622-6. PMID: 9335505
12. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.  |  Nakao, A., et al. 1997. Nature. 389: 631-5. PMID: 9335507

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Smad2 Antibody (YZ-13) has 41 citations in a variety of scientific publications.

Primary antibodies like Anti-Smad2 Antibody (YZ-13) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Smad2 Antibody (YZ-13) Specifications

Alternate Product Name: Smad2

Product Clone Name: YZ-13

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 181-280

Epitope Target: Smad2

Epitope Species: human

Product Reactivity/Detection: Smad2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 41 citations in various scientific publications

Available Conjugates/Forms for Smad2 Antibody (YZ-13): N/A

The preferred Smad2/3 antibody is Smad2/3 Antibody (C-8): sc-133098.